CytoSorbents Corp.

CytoSorbents Corp.

CytoSorbents Corp.

Overview
Date Founded

2014

Headquarters

7 Deer Park Drive, Suite K, Monmouth Junction, NJ, 08852, USA

Type of Company

Public

Employees (Worldwide)

153

Industries

Medical Products & Equipment
Pharmaceuticals
Biotechnology
Hospitals & Patient Services

Company Description

CytoSorbents Corp. engages in the critical care immunotherapy, investigation, and commercialization of blood purification technology. Its product portfolio include CytoSorb, ContrastSorb XL, HemoDefend, VetResQ, and DrugSorb. The company was founded by Joseph Rubin on April 25, 2002 and is headquartered in Monmouth Junction, NJ.

Contact Data
Trying to get in touch with decision makers at CytoSorbents Corp.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

President & Chief Executive Officer

President & Chief Operating Officer

Chief Financial Officer & Chief Accounting Officer

Chief Medical Officer

Director, Clinical Operations

Executive Vice President-Sales & Marketing

Vice President of Business Development

Assiociate Director of Polymer Development

Vice President-US Sales & Marketing

Program Manager

Board of Directors

Former President & Chief Executive Officer at MedaSorb Technologies LLC

Physician at CHHS Hospital Co. LLC

Founder at Certus Advisory Ltd.

Managing Member at Sobel & Co., LLC

Paths to CytoSorbents Corp.
Potential Connections via
Relationship Science
You
CytoSorbents Corp.
Owners & Shareholders
Details Hidden

Sectoral Asset Management specializes in managing global portfolios that invest in the healthcare sector. The firm employs a bottom-up investment approach that can be categorized as growth at a reasonable price (GARP). Investments are selected using a focused stock selection process based on primary research of company fundamentals and close contacts with company management to assess their scientific, business, financial and ESG aspects. Specific areas of interest include: Pharmaceuticals, Biotechs, Life Science Tools and Services, Medtechs and Healthcare Providers and Services, Healthcare Equipment and Supplies, and Healthcare Technology. Covered companies are blue-chips, main index constituents and companies with innovative programs identified through research and industry contacts, including recent IPOs. The investment process encompasses stock selection, portfolio construction and risk management.

Details Hidden

Skylands Capital generally invests in a varied portfolio of common stocks of U.S.-based corporations. They may also invest in any eligible investment including, but not limited to, fixed income securities, convertible securities, preferred stocks, equity options and foreign equity and debt securities. The funds may engage in futures transactions, sell short, employ leverage, purchase illiquid securities, trade IPOs and secondary public offerings, write put and call options, and use various derivative instruments for hedging, managing risk or enhancing returns. Certain separate accounts may make similar investments subject to the client's investment advisory agreement or as directed by the client.

Details Hidden

SIG begins the investment process by defining a client’s current situation and long-term investment goals. Their primary investment execution is through individual equity and fixed income securities, mutual funds and ETFs, which are combined into a customized, proprietary asset allocation for each client. The firm may also incorporate alternative and third-party manager’s investments within the client’s asset allocation.

Recent Transactions
Details Hidden

CytoSorbents Corp. issued USD Common Stock

Details Hidden

CytoSorbents Corp. issued . USD Common Stock

Details Hidden

CytoSorbents Corp. issued USD Common Stock

Insider Transactions
Details Hidden
Transaction Advisors
Escrow Agent

Advised onCytoSorbents Corp. issued USD Common Stock

Legal Advisor

Advised onCytoSorbents Corp. issued USD Common Stock

Underwriter

Advised onCytoSorbents Corp. issued USD Common Stock

Legal Advisor

Advised onCytoSorbents Corp. issued USD Common Stock

Managing Director, Medical Supplies & Devices

Advised onCytoSorbents Corp. issued USD Common Stock

Managing Director

Advised onCytoSorbents Corp. issued USD Common Stock

Advisors & Consultants
Scientific Advisor

Member, Scientific Advisory Board at CytoSorbents Corp.

Scientific Advisor

Member, Scientific Advisory Board at CytoSorbents Corp.

Scientific Advisor

Member, Scientific Advisory Board at CytoSorbents Corp.

Clients

Biocon, India's largest biotech company is focused on delivering affordable innovation. It is committed to reduce therapy costs of chronic diseases like diabetes, cancer and autoimmune diseases by leveraging India's cost advantage to deliver affordable healthcare solutions to patients, partners and healthcare systems across the globe. Biocon's key innovations include world's first Pichia based recombinant human Insulin, INSUGEN®, insulin analogue Glargine, BASALOG® and India's first indigenously produced monoclonal antibody BioMAb-EGFR®, for head & neck cancer. INSUPen® is a next generation affordable insulin delivery device introduced in India by Biocon. Its aspiration to become a US $ 1 billion company by FY 18 is fuelled by five powerful growth accelerators, Small Molecules, Biosimilars, Branded Formulations, Novel Molecules, and Research Services with a focus on emerging markets. Over the decades, Biocon has successfully evolved into an emerging global biopharma enterprise, serving its partners and customers in over 75 countries. As a fully integrated biopharma company it delivers innovative biopharmaceutical solutions, ranging from discovery to development and commercialization, leveraging the cutting edge science, cost-effective drug development capabilities and global scale manufacturing capacities, to move ideas to market. Leveraging India's globally competitive cost base and exceptional scientific talent, the Company is advancing its in-house R&D programs, and is also providing integrated research services to leading global pharmaceutical and biotechnology companies through Syngene and Clinigene. Biocon has rapidly developed a robust novel and biosimilars pipeline, focusing on Diabetes, Oncology and auto-immune diseases, which has several molecules at different stages of the development cycle. With the successful commercial launch of its first anti-cancer drug and several promising discovery partnerships in the clinic, the Company remains committed to scaling new heights in frontier science and achieving new milestones in affordable medicine

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services and Active Ingredients, Proprietary Products, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services and Active Ingredients segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API or bulk drugs, which are principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research, development, and manufacture of differentiated formulations and new chemical entities. The Others segment includes the operations of the wholly-owned subsidiary of the company, Aurigene Discovery Technologies Limited, a discovery stage biotechnology company developing novel and best-in-class therapies in the fields of oncology and inflammation and which works with pharmaceutical and biotechnology companies in early-stage collaborations, brining drug candidates for pre-clinical development. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

Fresenius Medical Care AG & Co. KGaA engages in the provision of products and services for patients with chronic kidney failure. It also develop and manufacture a variety of health care products, which includes dialysis and non-dialysis products. The company was founded on August 5, 1996 and is headquartered in Bad Homburg, Germany.

Key Stats and Financials As of 2019
Market Capitalization
$385M
Total Enterprise Value
$128M
Earnings Per Share
$-0.6
Revenue
$24.9M
Net Profit
$-19.3M
Total Equity
$3.42M
Enterprise Value / Sales
5.13x
TEVNet Income
-6.65x
Debt TEV
0.13x
EBITDAMargin
-73.72%
Total Debt
$16.1M
EBITDA
$-18.4M
Three Year Compounded Annual Growth Rate Of Revenue
37.83%
Non-Profit Donations & Grants Received
Competitors
Danaher Corporation Industrial Machinery & Manufacturing - Washington, DC

Danaher Corp. operates as a medical company, which designs, manufactures, and markets professional, medical, industrial and commercial products and services. It operates through the following segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines. The Diagnostics segment comprises of analytical instruments, reagents, consumables, software, and services that hospitals, physician's offices, reference laboratories, and other critical care settings use to diagnose disease and make treatment decisions. The Environmental & Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1969 and is headquartered in Washington, DC.

Medtronic Plc Medical Products & Equipment - Dublin, Irl

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiac and Vascular Group; Minimally Invasive Technologies Group; Restorative Therapies Group; and Diabetes Group. The Cardiac and Vascular Group segment consist Cardiac Rhythm and Heart Failure, Coronary and Structural Heart, and Aortic and Peripheral Vascular divisions. The Minimally Invasive Technologies Group segment comprises Surgical Innovations and Respiratory, Gastrointestinal, and Renal divisions. The Restorative Therapies Group contains Spine, Brain, Specialty Therapies, and Pain Therapies divisions. The Diabetes Group segment focuses in the development, manufacturing, and marketing of products and services for the management of Type I and Type II diabetes. The company was founded in 1949 and is headquartered in Dublin, Ireland.

bioMérieux SA Medical Products & Equipment - Marcy l’etoile, France

bioMérieux SA engages in the provision of in vitro diagnostic solutions, which determine the source of disease and contamination. The firm develops testing. detection, and other laboratory system for the analysis of cancer, diseases, and infections caused by bacteria, virus, and fungi. The company was founded Alain Mérieux in 1963 and is headquartered in Marcy l'Etoile, France.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by CytoSorbents Corp.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of CytoSorbents Corp.'s profile does not indicate a business or promotional relationship of any kind between RelSci and CytoSorbents Corp..